



Advancing Cell and Gene Therapies in California and Beyond

Lisa Kadyk, PhD
Associate Director, Therapeutics Development
Ultragenyx Rare Disease Bootcamp, Novato, CA
November 8, 2023




OUR MISSION

Accelerating world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world



Proposition 71
2004

\$3B Bond
Funding



Proposition 14
2020

\$5.5B Bond
Funding



DISCOVERY



TRANSLATION



CLINICAL




EDUCATION




INFRASTRUCTURE

**\$3.6B research funding investments
from 2004-present**

- 96 Clinical Trials funded through November 2023
- Wide Variety of Diseases and Disorders
- Different Approaches




CIRM Rare Disease Portfolio by Stage



70 active awards for rare disease therapy development (of 180) = 39%

Active Awards Rare Disease Portfolio by Approach



Core Funding Opportunities



DISCOVERY

New Idea



Single Product Candidate



TRANSLATION



Pre-IND Meeting or Equivalent



CLINICAL



Approved Therapy or Device

\$63M

3x a Year*

\$85M

2x a Year

\$252M

Monthly deadlines

* Three different types of call



DISC2

Candidate

Funding Limit

Therapeutic	Stem Cell, Gene Therapy Biologic*, Small Molecule*	\$1.5M
Diagnostic	Stem-cell based, <i>or</i> Addresses a bottleneck for stem cell or gene therapies	\$500K
Medical Device		\$500K
Tool		\$500K

DISC2 1x/year

*Must act on a stem cell



	Aim / Scope	Eligibility	Funding Limit
--	-------------	-------------	---------------

TRAN 1

Therapeutic

Stem Cell, Gene Therapy
Biologic* or Small Molecule*
*Must act on a stem cell

\$4M / \$2M**
** \$2M small molecule

TRAN 2

Diagnostic

Support Stem Cell, Gene
Therapy or Combination

\$1.2M

TRAN 3

Medical Device

Critical to Stem Cell, Gene
Therapy or Combination

\$2M

TRAN 4

Tool

Address Bottlenecks to Stem
Cell, Gene Therapy or
Combination

\$1M

Offered 2x/year



Aim / Scope

Eligibility

Funding Limit

CLIN 1

IND Enabling

Pre-IND Meeting

Non-profit \$6M
For-profit \$4M

CLIN 2

Clinical Trial

Active IND

	<u>FIH*</u>	<u>After FIH</u>
Non-profit	\$12M	\$15M
For-profit	\$8M	\$15M

*First in Human trial

- Monthly application deadlines
- Three months to funding (if successful)

DEI principles are incorporated into all our initiatives

- Racial, ethnic, socio-economic, geographic diversity on research teams and for clinical trial participants
- Cultural sensitivity training for teams
- Active outreach and retention programs for clinical trials
- Grant applications receive a “DEI” score in addition to a science score

CIRM Resources to Facilitate Success

Convened for Clinical and Translational Awardees

Include Science/Clinical advisor and Patient Advocate

Discuss challenges and plan for success



Resources for Success: Alpha Clinics Network



- Accelerating cell and gene-therapy clinical trials
- Patient-centered care, specialized clinical skillsets
- Over 100 trials supported
- Over \$100M industry contracts

New Alpha Clinics added 2022: Stanford, Cedars-Sinai, USC

Thank You!

lkadyk@cirm.ca.gov

Please visit us at:
www.cirm.ca.gov



